Cell-Medicine

Cell-Medicine is a private Japanese oncology biotech founded out of RIKEN and focused on personalized cancer immunotherapy. Its core technology is Autologous Formalin-fixed Tumor Vaccine (AFTVac), an individualized therapeutic cancer vaccine prepared from a patient's own formalin-fixed or paraffin-embedded tumor tissue together with immunoadjuvants. The company has reported clinical use and investigator-led clinical studies in Japan, particularly in glioblastoma multiforme and hepatocellular carcinoma, and also highlights breast cancer outcomes on its website. In addition to direct patient use in Japan, Cell-Medicine positions AFTVac as a licensable platform for global partners. The company appears to operate as a small private venture with a focused pipeline centered on a single personalized cancer vaccine platform.